Recombinant MDV1 Viral Vector for Stable Antigen Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current recombinant HVT-based vaccines for poultry face interference issues when used in combination, leading to reduced protection against multiple avian pathogens, and existing recombinant Marek's disease viruses of serotype 1 have not provided satisfactory results for stable protein expression and long-term immunity.
Innovation Solution
Development of novel recombinant Marek's disease viruses of serotype 1 (rMDV1) with foreign genes cloned into specific untranslated genetic regions of the genome, allowing for stable expression and combination with other viral vaccines without cross-interference, thereby inducing strong immune protection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If recombinant HVT-based vaccines are used in combination to confer immunogenicity against distinct pathogens, then protection against multiple diseases is achieved, but interference occurs leading to lower protection against at least one disease
Solution Approach 1:
The patent uses MDV1 as an intermediary viral vector that does not interfere with HVT-based vaccines. By selecting a different herpesvirus serotype (MDV1 instead of HVT), the invention creates a compatible platform for multivalent vaccination that avoids the interference problem between multiple HVT recombinants while maintaining the ability to express multiple antigens
Solution Approach 2:
The patent changes the viral vector parameter from HVT to MDV1 (different herpesvirus serotype). This parameter change resolves the interference issue while preserving the multivalent vaccination capability, as MDV1 and HVT are different serotypes that do not compete for the same cellular receptors or interfere with each other's replication and antigen expression
2Duration of action of stationary object
If foreign genes are integrated into viral vectors to create viral-vectored vaccines, then duration of immunity is increased, but stable protein expression is not achieved with existing MDV1 recombinants
Solution Approach 1:
The patent optimizes the genetic construction parameters of MDV1 recombinants by integrating foreign genes into specific genomic locations and using appropriate promoters. This results in stable protein expression while maintaining the latent infection capability that provides long-duration immunity
Solution Approach 2:
The patent performs preliminary optimization of the MDV1 genetic construct design before vaccination, ensuring that foreign genes are properly integrated and will be stably expressed. This preliminary action prevents expression instability issues that would otherwise occur during the vaccination process
3Reliability
If recombinant viruses are designed to express foreign pathogen proteins, then specific and protective immunity is induced, but cross-interference occurs when multiple recombinant viruses are used
Solution Approach 1:
The patent uses MDV1 as an intermediary viral vector that serves as a compatible platform for expressing multiple antigens without interfering with other vaccines. MDV1 acts as a mediator that can be combined with HVT-based vaccines and other viral vectors without causing cross-interference, thereby enabling versatile multivalent vaccination strategies
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to recombinant MDV1 viruses and the uses thereof. The invention is particularly suited to vaccinate poultry against avian pathogens.